Navigation Links
Orcrist Bio Inc. Files with European Competent Authority for a Phase I, Open-label, Single-ascending-dose, Safety Study of HYC750
Date:2/9/2009

CALGARY, Feb. 9 /PRNewswire/ - Orcrist Bio Inc. (ORC) a biotech company developing stem cell-mobilizing pharmaceuticals, announced today that it has filed with the European Competent Authority in Seville, Spain, a Phase I, open-label, single-ascending-dose, safety study of HYC750 in healthy male volunteers. The goal of the study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics (induction of hematopoiesis) of HYC750, a patent-protected formulation of hyaluronan. ORC utilized the regulatory expertise and experience of Kinesis Pharma BV (Breda, Netherlands) to develop the clinical trial submission. The planned study is to be conducted by InPEC BV (Breda, Netherlands) at their clinical trial site in Malaga, Spain.

Dr. Thomas Ichim, Chairman of ORC's Scientific Advisory Board commented "HYC750 possesses a very favourable pharmacological and pharmaceutical profile and is an excellent candidate for aggressive and rapid clinical development."

"Filing the requisite regulatory documentation with the European authorities to initiate our Phase I clinical trial was a major accomplishment for our company and represents Orcrist's most important milestone thus far," said Dr. Brett Schönekess, President and CEO of Orcrist. "We are thrilled with the expertise and professionalism provided by both Kinesis and InPEC, and are very excited to see the HYC750 clinical program move forward. Our clinical goal is to confirm the safety profile of HYC750 and to see a clear illustration of its stem cell mobilization properties, which would support its future development as a treatment for chemotherapy-related blood cell depletion."

"We are very honored to be chosen by Orcrist to coordinate and perform their Phase I study with HYC750 and we look forward to the future initiation of the trial" commented Dr. Ronald van der Geest, Chief Business Officer of InPEC BV. "Orcrist, Kinesis, and InPEC have worked as a team on this project, and I beli
'/>"/>

SOURCE Orcrist Bio Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Tigris Pharmaceuticals Files IND Application for GGTI-2418
2. Panda Ethanols Hereford, Texas Subsidiary Files Voluntary Chapter 11
3. Stem Cell Innovations, Inc., Files New Patent Application
4. Helix BioPharma Files Form 20-F Registration Statement With the U.S. Securities and Exchange Commission
5. ISTA Pharmaceuticals Files New Drug Application with U.S. FDA for Bepreve(TM)
6. 3SBio Inc. Files for SFDA Approval of NuLeusin
7. 3SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO
8. Sangui BioTech International, Inc. Files Remaining Reports
9. VentriPoint Diagnostics Files Management Discussion and Analysis, Unaudited Financial Results for 2Q 2008
10. China-Biotics, Inc. Files Application for Nasdaq Listing
11. Terumo Cardiovascular Systems Files Patent Infringement Complaint Against Maquet Affiliates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... INCLINE VILLAGE, Nev. , Sept. 17, 2014  PDL ... notified by its independent registered accounting firm, Ernst & Young ... The resignation was confirmed in a letter delivered to the ... 8-K filed on September 16, 2014.  PDL ... "We have received a number of inquiries on ...
(Date:9/17/2014)... SAN FRANCISCO , Sept. 17, 2014 /PRNewswire/ ... patients receiving accelerated partial breast irradiation (APBI) via ... and those with positive lymph nodes could be ... for Radiation Oncology (ASTRO) guidelines place these patients ... an abstract at the 2014 ASTRO meeting, Beaumont ...
(Date:9/17/2014)... 17, 2014 The global consumption of squalene / ... is a natural skin-identical chemical that finds applications in various ... supplements, pharmaceuticals, and in other applications like high grade lubrication, ... a few major players and is regionally segregated. Sophim ( ... Oil Co. Ltd. ( Japan ), SeaDragon Marine ...
(Date:9/17/2014)... SEATTLE, WA , Sept. 17, 2014 /PRNewswire/ - ... that it intends to offer and sell shares of ... in separate but concurrent underwritten public offerings.  The Series ... shares of Oncothyreon Common Stock, provided that conversion will ... its affiliates would beneficially own more than 4.99% of ...
Breaking Biology Technology:PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 2PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 2Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 4Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 2Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 3Oncothyreon Announces Proposed Public Offerings 2
... Sept. 26 MacroGenics, Inc. announced,today that Mr. ... of the,company,s Board of Directors. With more than ... in the pharmaceutical and,biotechnology industry, Mr. Buchalter is ... MacroGenics as the company matures toward,commercializing its pipeline. ...
... XTL,Biopharmaceuticals Ltd. (NASDAQ: XTLB ; LSE: ... 2007, the Company received a NASDAQ Staff,Determination indicating ... minimum,$10 million shareholders, equity requirement for continued listing ... Marketplace Rule 4450(a)(3), and that,its ADRs are, therefore, ...
... Empowers Life Sciences Community with accelerated BioInformatics, ... Corp., announced,the initiation of Progeniq Pte Ltd, ... Singapore, into the BioIT Alliance today. The,BioIT ... integrate science and,technology to accelerate the pace ...
Cached Biology Technology:Jeffrey H. Buchalter Joins MacroGenics Board of Directors as Chairman 2Jeffrey H. Buchalter Joins MacroGenics Board of Directors as Chairman 3XTL to Appeal NASDAQ Staff Determination; XTL May Transfer its ADR Listing to the NASDAQ Capital Market 2XTL to Appeal NASDAQ Staff Determination; XTL May Transfer its ADR Listing to the NASDAQ Capital Market 3Progeniq Joins Microsoft in Bio IT Alliance 2Progeniq Joins Microsoft in Bio IT Alliance 3
(Date:9/17/2014)... care to reproductive technologies, the justice and well-being ... people to identify key issues, articulate their values ... the most defensible ways forward. But what are ... conversations?, The Hastings Center and the Presidential Commission ... up to publish a series of essays to ...
(Date:9/17/2014)... atmospheric scientists were instrumental in the creation of the ... to classify the fire threat potential of the powerful, ... spark into an inferno. The index was introduced Sept. ... UCLA and San Diego Gas and Electric. , The ... "extreme" that will be used to help fire agencies ...
(Date:9/17/2014)... Humanities has received a $260,000 grant from the Andrew ... of the Human in the Age of the Life ... of events aimed at exploring two compelling themes in ... who are exploring the boundaries of our self-definition as ... other involves the increasingly influential hypothesis that we are ...
Breaking Biology News(10 mins):Why bioethics literacy matters 2Why bioethics literacy matters 3UCLA scientists play key role in developing new Santa Ana Wildfire Threat Index 2Mellon Foundation awards grant for major project in the humanities and sciences 2
... Research led by T. Cooper Woods, PhD, Assistant Professor ... Center New Orleans, and Director of the Molecular Cardiology ... mechanism of how a drug commonly used on stents ... movement which is critical to wound healing and the ...
... TORONTO (April 13, 2010) -- An investigational intervention using ... thinking abilities of a group of mild- to moderate-stage ... rate of atrophy (shrinkage) of their brains, according to ... Center. These and other findings from the Phase II ...
... the Department of Computer Science at Virginia Tech have used ... by scientists in their quest to define the microbial DNA ... computers from across the world, the mpiBLAST computational tool used ... 90 years it would have required if the work were ...
Cached Biology News:Research discovery may lead to advances in heart disease and cancer treatment 2Investigational immune intervention slows brain shrinkage in Alzheimer's patients 2Investigational immune intervention slows brain shrinkage in Alzheimer's patients 3Investigational immune intervention slows brain shrinkage in Alzheimer's patients 4High-performance computing reveals missing genes 2High-performance computing reveals missing genes 3
...
... The Bio-Plex maintenance, calibration, ... is a custom 96-well plate ... validation, and calibration procedures using ... This MCV plate is for ...
Mynox is intended for research use only. Mynox is used for the elimination of Mycoplasma and Acholeplasma in cell and virus cultures, and other biologicals....
... PCR detection system holds 48 x 0.2 ml ... 48 LEDs independently excites fluorescence (470-500 nm) for ... detects emitted light (523-543 nm and 540-700 nm). ... cycler, whose Peltier heat pumps provide superb thermal ...
Biology Products: